GlassScriptPhysician profile
Dineshkumar M Thakur
NPI 1245243716
$4,360.41
in general payments reported to CMS, 2019-2025
43 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $193 · 2021: $141 · 2022: $721 · 2023: $1,219 · 2024: $967 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,006.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $898.21 | 2020-2025 | Keytruda, Verquvo, Lynparza |
| Novartis Pharmaceuticals Corporation | $401.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $280.24 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.18 | 2019-2024 | Jardiance |
| Amgen INC. | $249.70 | 2019-2025 | Lumakras, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $201.15 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $154.69 | 2019-2025 | Eliquis, Camzyos |
| Janssen Biotech, INC. | $141.52 | 2022-2024 | Darzalex, Imbruvica, Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $117.36 | 2020-2025 | Iclusig, Ninlaro |
| Eisai INC. | $115.88 | 2022-2024 | |
| Novo Nordisk INC | $115.80 | 2023 | |
| Agios Pharmaceuticals, INC. | $106.67 | 2024 | Pyrukynd |
| Biotronik INC. | $94.85 | 2024 | Amvia Edge |
| Pfizer INC. | $89.62 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $85.77 | 2022-2023 | Libtayo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $85.11 | 2020-2024 | Enhertu |
| Celgene Corporation | $79.88 | 2020-2023 | Opdualag |
| Edwards Lifesciences Corporation | $73.44 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $69.02 | 2023-2025 | |
| Caris Mpi, INC. | $59.93 | 2025 | Mi Cancer Seek |
| Emmaus Medical, INC. | $58.88 | 2023-2024 | Endari |
| Abbvie INC. | $51.77 | 2023 | Venclexta |
| Boston Scientific Corporation | $49.82 | 2025 | Lux-Dx Insertable Cardiac Monitor |
| Sobi, INC | $46.71 | 2023 | |
| Beigene USA, INC. | $36.08 | 2023 | Brukinsa |
| Seagen INC. | $34.99 | 2023 | Tukysa |
| Dendreon Pharmaceuticals LLC | $32.77 | 2022 | |
| Taiho Oncology, INC. | $32.53 | 2025 | |
| Servier Pharmaceuticals LLC | $31.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.82 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $28.15 | 2023 | Arcalyst |
| Philips North America LLC | $24.28 | 2025 | Mcot |
| Ipsen Biopharmaceuticals, INC | $24.12 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.03 | 2024 | Ultomiris |
| Esperion Therapeutics, INC. | $23.65 | 2025 | Nexletol |
| Genzyme Corporation | $23.16 | 2022 | |
| Exelixis INC. | $22.59 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $21.02 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.49 | 2025 | Lifevest |
| Novocure INC. | $20.34 | 2025 | Optune Lua (Novottf-200t) |
| Tempus Ai, INC | $18.71 | 2025 | Xt Cdx |
| Impulse Dynamics (USA) INC. | $15.17 | 2022 | |
| Lundbeck LLC | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dineshkumar Thakur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.